AtriCure (ATRC) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ATRC Stock Forecast

AtriCure stock forecast is as follows: an average price target of $49.57 (represents a 42.77% upside from ATRC’s last price of $34.72) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

ATRC Price Target

The average price target for AtriCure (ATRC) is $49.57 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $81.00 to $26.00. This represents a potential 42.77% upside from ATRC's last price of $34.72.

ATRC Analyst Ratings

Buy

According to 5 Wall Street analysts, AtriCure's rating consensus is 'Buy'. The analyst rating breakdown for ATRC stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

AtriCure Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jul 31, 2024	Rick Wise	Stifel Nicolaus	$26.00	$22.00	18.18%	-25.12%
Jul 31, 2024	Matt O'Brien	Piper Sandler	$40.00	$22.00	81.82%	15.21%
Jul 31, 2024	Marie Thibault	BTIG	$53.00	$22.00	140.91%	52.65%
May 02, 2024	Mike Matson	Needham	$40.00	$24.76	61.55%	15.21%
May 02, 2024	Marie Thibault	BTIG	$58.00	$24.76	134.25%	67.05%
Apr 23, 2024	Suraj Kalia	Oppenheimer	$32.00	$22.71	40.91%	-7.83%
Feb 06, 2023	-	Canaccord Genuity	$81.00	$47.20	71.61%	133.29%
Dec 19, 2022	Mike Matson	Needham	$58.00	$41.37	40.20%	67.05%
Aug 03, 2022	Matt O'Brien	Piper Sandler	$55.00	$49.69	10.69%	58.41%
May 04, 2022	-	Needham	$67.00	$54.63	22.64%	92.97%

Row per page

Go to

The latest AtriCure stock forecast, released on Jul 31, 2024 by Rick Wise from Stifel Nicolaus, set a price target of $26.00, which represents a 18.18% increase from the stock price at the time of the forecast ($22.00), and a -25.12% decrease from ATRC last price ($34.72).

AtriCure Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	6
Avg Price Target	-	-	$41.50
Last Closing Price	$34.72	$34.72	$34.72
Upside/Downside	-100.00%	-100.00%	19.53%

In the current month, the average price target of AtriCure stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to AtriCure's last price of $34.72. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 30, 2024	Oppenheimer	Outperform	Outperform	Hold
Oct 30, 2024	UBS	Buy	Buy	Hold
Jul 31, 2024	Needham	Underperform	Underperform	Hold
Jul 31, 2024	Piper Sandler	Buy	Buy	Hold
Jul 31, 2024	Piper Sandler	Overweight	Overweight	Hold
Jul 31, 2024	BTIG	Buy	Buy	Hold
Jul 08, 2024	Oppenheimer	Buy	Buy	Hold
Jul 08, 2024	Needham	Underperform	Underperform	Hold
May 02, 2024	Oppenheimer	Underperform	Underperform	Hold
May 02, 2024	UBS	Buy	Buy	Hold

Row per page

Go to

AtriCure's last stock rating was published by Oppenheimer on Oct 30, 2024. The company gave ATRC a "Outperform" rating, the same as its previous rate.

AtriCure Financial Forecast

AtriCure Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$98.29M	$100.92M	$93.49M	$88.03M	$83.25M	$84.53M	$74.58M	$73.22M	$70.46M	$71.38M	$59.27M	$57.73M	$54.76M	$40.82M	$53.23M	$61.32M	$56.61M
Avg Forecast	$152.69M	$147.10M	$147.45M	$137.69M	$136.68M	$131.27M	$132.02M	$123.32M	$119.85M	$112.23M	$116.24M	$106.86M	$103.68M	$96.65M	$97.55M	$88.48M	$87.78M	$81.79M	$79.60M	$71.17M	$72.66M	$68.59M	$61.09M	$56.06M	$58.02M	$49.37M	$35.94M	$55.50M	$60.07M	$55.12M
High Forecast	$153.85M	$148.21M	$148.57M	$138.73M	$137.71M	$132.26M	$133.01M	$124.26M	$120.10M	$112.24M	$116.24M	$106.88M	$104.46M	$99.02M	$98.28M	$89.15M	$88.44M	$81.79M	$79.60M	$71.17M	$72.66M	$68.59M	$61.09M	$56.06M	$58.02M	$49.37M	$35.94M	$55.50M	$60.07M	$55.12M
Low Forecast	$151.66M	$146.10M	$146.45M	$136.76M	$135.75M	$130.38M	$131.12M	$122.76M	$119.59M	$112.22M	$116.24M	$106.83M	$102.97M	$95.42M	$96.89M	$87.88M	$87.18M	$81.79M	$79.60M	$71.17M	$72.66M	$68.59M	$61.09M	$56.06M	$58.02M	$49.37M	$35.94M	$55.50M	$60.07M	$55.12M
# Analysts	4	4	4	4	3	3	3	5	6	3	1	1	1	8	5	4	4	3	4	3	5	4	5	4	5	9	9	9	8	8
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.02%	1.03%	1.06%	1.00%	1.02%	1.06%	1.05%	1.01%	1.03%	1.17%	1.06%	0.99%	1.11%	1.14%	0.96%	1.02%	1.03%

AtriCure's average Quarter revenue forecast for Dec 23 based on 1 analysts is $103.68M, with a low forecast of $102.97M, and a high forecast of $104.46M. ATRC's average Quarter revenue forecast represents a 5.48% increase compared to the company's last Quarter revenue of $98.29M (Sep 23).

AtriCure EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	6	3	1	1	1	8	5	4	4	3	4	3	5	4	5	4	5	9	9	9	8	8
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-8.09M	$-4.14M	$-5.78M	$-4.14M	$-10.72M	$-13.66M	$-11.26M	$-9.77M	$101.42M	$-12.33M	$-13.57M	$-15.10M	$-1.24M	$-4.54M	$-12.73M	$-12.41M	$-5.78M
Avg Forecast	$-15.27M	$-14.71M	$-14.74M	$-13.77M	$-13.67M	$-13.12M	$-13.20M	$-12.33M	$-11.98M	$-11.22M	$-11.62M	$-13.20M	$-10.37M	$-9.66M	$-9.75M	$-12.00M	$-9.10M	$-16.90M	$-16.45M	$-10.91M	$-15.01M	$-14.17M	$-12.62M	$-13.21M	$-11.99M	$-10.20M	$-7.43M	$-12.42M	$-12.41M	$-11.39M
High Forecast	$-15.16M	$-14.61M	$-14.64M	$-13.67M	$-13.57M	$-13.04M	$-13.11M	$-12.27M	$-11.96M	$-11.22M	$-11.62M	$-10.56M	$-10.30M	$-9.54M	$-9.69M	$-9.60M	$-7.28M	$-16.90M	$-16.45M	$-8.73M	$-15.01M	$-14.17M	$-12.62M	$-10.57M	$-11.99M	$-10.20M	$-7.43M	$-9.93M	$-12.41M	$-11.39M
Low Forecast	$-15.38M	$-14.82M	$-14.85M	$-13.87M	$-13.77M	$-13.22M	$-13.30M	$-12.42M	$-12.01M	$-11.22M	$-11.62M	$-15.84M	$-10.44M	$-9.90M	$-9.83M	$-14.40M	$-10.91M	$-16.90M	$-16.45M	$-13.09M	$-15.01M	$-14.17M	$-12.62M	$-15.85M	$-11.99M	$-10.20M	$-7.43M	$-14.90M	$-12.41M	$-11.39M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.84%	0.42%	0.48%	0.45%	0.63%	0.83%	1.03%	0.65%	-7.16%	0.98%	1.03%	1.26%	0.12%	0.61%	1.03%	1.00%	0.51%

5 analysts predict ATRC's average Quarter EBITDA for Dec 21 to be $-15.01M, with a high of $-15.01M and a low of $-15.01M. This is -114.80% lower than AtriCure's previous annual EBITDA (Sep 21) of $101.42M.

AtriCure Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	6	3	1	1	1	8	5	4	4	3	4	3	5	4	5	4	5	9	9	9	8	8
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-9.05M	$-5.12M	$-6.48M	$-4.17M	$-12.27M	$-14.84M	$-15.18M	$-13.74M	$97.11M	$-16.25M	$-16.92M	$-18.56M	$-4.95M	$-8.24M	$-16.41M	$-16.10M	$-9.36M
Avg Forecast	$-2.80M	$-4.77M	$-5.04M	$-7.94M	$-5.23M	$-7.18M	$-7.48M	$-9.99M	$-10.97M	$-9.18M	$-7.92M	$-17.80M	$-10.59M	$-14.34M	$-13.95M	$-16.18M	$-12.79M	$-12.05M	$-13.75M	$-14.71M	$-13.60M	$-15.27M	$-15.71M	$-16.46M	$-13.13M	$-15.95M	$-27.14M	$-16.01M	$-19.63M	$-14.76M
High Forecast	$-2.78M	$-4.73M	$-4.99M	$-7.87M	$-5.18M	$-7.11M	$-7.41M	$-8.69M	$-5.22M	$-9.10M	$-7.85M	$-14.24M	$-9.63M	$-12.03M	$-13.83M	$-12.94M	$-10.23M	$-12.05M	$-13.75M	$-11.77M	$-13.60M	$-15.27M	$-15.71M	$-13.17M	$-13.13M	$-15.95M	$-27.14M	$-12.81M	$-19.63M	$-14.76M
Low Forecast	$-2.83M	$-4.82M	$-5.09M	$-8.01M	$-5.28M	$-7.25M	$-7.55M	$-10.43M	$-21.94M	$-9.27M	$-7.99M	$-21.36M	$-11.07M	$-15.73M	$-14.09M	$-19.42M	$-15.35M	$-12.05M	$-13.75M	$-17.65M	$-13.60M	$-15.27M	$-15.71M	$-19.75M	$-13.13M	$-15.95M	$-27.14M	$-19.21M	$-19.63M	$-14.76M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.63%	0.37%	0.40%	0.33%	1.02%	1.08%	1.03%	1.01%	-6.36%	1.03%	1.03%	1.41%	0.31%	0.30%	1.03%	0.82%	0.63%

AtriCure's average Quarter net income forecast for Dec 21 is $-13.60M, with a range of $-13.60M to $-13.60M. ATRC's average Quarter net income forecast represents a -114.01% decrease compared to the company's last Quarter net income of $97.11M (Sep 21).

AtriCure SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	6	3	1	1	1	8	5	4	4	3	4	3	5	4	5	4	5	9	9	9	8	8
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$61.60M	$63.78M	$60.06M	$55.50M	$57.27M	$62.39M	$56.12M	$53.71M	$49.87M	$56.96M	$49.21M	$49.07M	$33.75M	$24.90M	$42.75M	$47.00M	$40.28M
Avg Forecast	$107.24M	$103.31M	$103.56M	$96.70M	$95.99M	$92.19M	$92.71M	$86.61M	$84.17M	$78.82M	$81.63M	$65.78M	$72.81M	$67.88M	$68.51M	$59.80M	$49.99M	$57.50M	$55.96M	$54.36M	$51.08M	$48.22M	$42.95M	$47.88M	$40.79M	$34.71M	$25.27M	$41.71M	$42.23M	$38.75M
High Forecast	$108.05M	$104.09M	$104.34M	$97.43M	$96.71M	$92.89M	$93.41M	$87.27M	$84.35M	$78.83M	$81.63M	$78.93M	$73.36M	$69.54M	$69.03M	$71.76M	$59.99M	$57.50M	$55.96M	$65.23M	$51.08M	$48.22M	$42.95M	$57.45M	$40.79M	$34.71M	$25.27M	$50.05M	$42.23M	$38.75M
Low Forecast	$106.51M	$102.60M	$102.85M	$96.04M	$95.34M	$91.56M	$92.08M	$86.22M	$83.99M	$78.81M	$81.63M	$52.62M	$72.32M	$67.01M	$68.04M	$47.84M	$39.99M	$57.50M	$55.96M	$43.49M	$51.08M	$48.22M	$42.95M	$38.30M	$40.79M	$34.71M	$25.27M	$33.37M	$42.23M	$38.75M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.91%	0.93%	1.00%	1.11%	1.00%	1.11%	1.03%	1.05%	1.03%	1.33%	1.03%	1.20%	0.97%	0.99%	1.03%	1.11%	1.04%

AtriCure's average Quarter SG&A projection for Dec 23 is $72.81M, based on 1 Wall Street analysts, with a range of $72.32M to $73.36M. The forecast indicates a 18.19% rise compared to ATRC last annual SG&A of $61.60M (Sep 23).

AtriCure EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	6	3	1	1	1	8	5	4	4	3	4	3	5	4	5	4	5	9	9	9	8	8
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.20	$-0.11	$-0.14	$-0.09	$-0.27	$-0.32	$-0.33	$-0.30	$2.15	$-0.36	$-0.38	$-0.42	$-0.11	$-0.20	$-0.42	$-0.42	$-0.25
Avg Forecast	$-0.06	$-0.10	$-0.11	$-0.17	$-0.11	$-0.15	$-0.16	$-0.21	$-0.23	$-0.19	$-0.17	$-0.23	$-0.22	$-0.30	$-0.30	$-0.31	$-0.18	$-0.26	$-0.29	$-0.32	$-0.29	$-0.33	$-0.34	$-0.39	$-0.28	$-0.34	$-0.58	$-0.41	$-0.42	$-0.31
High Forecast	$-0.06	$-0.10	$-0.11	$-0.17	$-0.11	$-0.15	$-0.16	$-0.18	$-0.11	$-0.19	$-0.17	$-0.23	$-0.20	$-0.26	$-0.29	$-0.31	$-0.17	$-0.26	$-0.29	$-0.32	$-0.29	$-0.33	$-0.34	$-0.39	$-0.28	$-0.34	$-0.58	$-0.41	$-0.42	$-0.31
Low Forecast	$-0.06	$-0.10	$-0.11	$-0.17	$-0.11	$-0.15	$-0.16	$-0.22	$-0.47	$-0.20	$-0.17	$-0.23	$-0.23	$-0.33	$-0.30	$-0.31	$-0.18	$-0.26	$-0.29	$-0.32	$-0.29	$-0.33	$-0.34	$-0.39	$-0.28	$-0.34	$-0.58	$-0.41	$-0.42	$-0.31
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.66%	0.37%	0.45%	0.52%	1.05%	1.09%	1.03%	1.03%	-6.60%	1.07%	0.98%	1.50%	0.32%	0.35%	1.01%	1.00%	0.79%

According to 5 Wall Street analysts, AtriCure's projected average Quarter EPS for Dec 21 is $-0.29, with a low estimate of $-0.29 and a high estimate of $-0.29. This represents a -113.49% decrease compared to ATRC previous annual EPS of $2.15 (Sep 21).

AtriCure Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ANGO	AngioDynamics	$6.88	$15.00	118.02%	Buy
ATRC	AtriCure	$34.72	$49.57	42.77%	Buy
CNMD	CONMED	$70.77	$96.00	35.65%	Buy
LMAT	LeMaitre Vascular	$103.55	$85.25	-17.67%	Buy

ATRC Forecast FAQ

Is AtriCure a good buy?

Yes, according to 5 Wall Street analysts, AtriCure (ATRC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of ATRC's total ratings.

What is ATRC's price target?

AtriCure (ATRC) average price target is $49.57 with a range of $26 to $81, implying a 42.77% from its last price of $34.72. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will AtriCure stock go up soon?

According to Wall Street analysts' prediction for ATRC stock, the company can go up by 42.77% (from the last price of $34.72 to the average price target of $49.57), up by 133.29% based on the highest stock price target, and down by -25.12% based on the lowest stock price target.

Can AtriCure stock reach $50?

ATRC's highest twelve months analyst stock price target of $81 supports the claim that AtriCure can reach $50 in the near future.

What are AtriCure's analysts' financial forecasts?

AtriCure's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $523.29M (high $527.24M, low $520.01M), average EBITDA is $-52.319M (high $-51.991M, low $-52.714M), average net income is $-29.874M (high $-28.395M, low $-30.503M), average SG&A $367.5M (high $370.28M, low $365.2M), and average EPS is $-0.634 (high $-0.603, low $-0.648). ATRC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $584.94M (high $589.35M, low $580.96M), average EBITDA is $-58.483M (high $-58.085M, low $-58.924M), average net income is $-20.549M (high $-20.367M, low $-20.751M), average SG&A $410.8M (high $413.9M, low $408.01M), and average EPS is $-0.436 (high $-0.432, low $-0.441).

Did the ATRC's actual financial results beat the analysts' financial forecasts?

Based on AtriCure's last annual report (Dec 2023), the company's revenue was $399.24M, beating the average analysts forecast of $386.35M by 3.34%. Apple's EBITDA was $-26.683M, missing the average prediction of $-41.781M by -36.14%. The company's net income was $-30.438M, missing the average estimation of $-55.065M by -44.72%. Apple's SG&A was $253.14M, missing the average forecast of $268.99M by -5.89%. Lastly, the company's EPS was $0, missing the average prediction of $-1.136 by -100.00%. In terms of the last quarterly report (Sep 2023), AtriCure's revenue was $98.29M, beating the average analysts' forecast of $96.65M by 1.70%. The company's EBITDA was $-8.089M, missing the average prediction of $-9.663M by -16.29%. AtriCure's net income was $-9.055M, missing the average estimation of $-14.344M by -36.87%. The company's SG&A was $61.6M, missing the average forecast of $67.88M by -9.24%. Lastly, the company's EPS was $-0.2, missing the average prediction of $-0.305 by -34.32%